加速超分割放射治疗非小细胞肺癌初期疗效观察  

HYPERFRACTIONATED ACCELERATED RADIOTHERAPY FOR NON-SMALL CELL LUNG CANCER(A Preliminary Report)

作　　者：傅小龙[1] 蒋国樑[1] 王丽娟[1] 钱浩[1] 傅深[1] 叶明[1] 赵森[1] 

机构地区：[1]上海医科大学附属肿瘤医院

出　　处：《中国癌症杂志》1996年第1期45-48,共4页China Oncology

基　　金："国家肺癌八五攻关课题"资助

摘　　要：目的观察加速超分割放射（ＨＡＲＴ）治疗非小细胞肺癌（ＮＳＣＬＣ）的即期疗效及早期放射反应。方法６３例ＮＳＣＬＣ入选ＨＡＲＴ组，取同期常规治疗７７例作为对照组（ＣＦ组）。ＨＡＲＴ组放射，每次１．１０Ｇｙ（±０．０２Ｇｙ），每天３次，每周５天，肿瘤灶总剂量为７２～７６Ｇｙ／６６～６９次／３３天（２９～４２天）。ＣＦ组每天１次，每周５天，总剂量为６２～６５Ｇｙ／３２～３６次／４８天（１２～５２天）。中位总疗程时间，ＨＡＲＴ较ＣＦ短１５天。结果ＨＡＲＴ组有３例不能耐受而终止放疗，８７％有放射性食管炎，而ＣＦ组仅５８％（Ｐ＝０．００１），原发灶完全缓解＋部分缓解（ＣＲ＋ＰＲ）为８０％，而ＣＦ组为５８％（Ｐ＝０．０２７）。结论ＨＡＲＴ为患者能耐受新的非常规分割方法，能提高ＮＳＣＬＣ的即期疗效。PURPOSE To assess the immediate results and early reactions of hyperfractionated accelerated radiotherapy (HART) of non-small cell lung cancer (NSCLC).METHODS From Dec. 1991 to Dec. 1994,HART protocal was used to treat 63 cases of NSCLC patients,while 77 cases treated by conventional fractionation radiotherapy (CF) during the same period were used as controls. The HART schedule used in our clinical trial has been modified from 36 fractions of 1.5Gy tid in 12 days to 72 fractions of 1.1Gy in 22￣23 treatment days at 5 days per week. The total tumor dose was 72￣76Gy/66￣69 F/33d (29￣42days). In the CF group,the total tumor dose was 62￣65Gy/32￣ 36F/48d (42￣52days) was given at 1 fraction/day at 5 days/week. The median overall treatment time of HART was reduced by 15 days as compared to that of CF.RESULTS Three patients could not tolerate the HART protocol toxicity. There was no significant difference in early radiation morbidities of normal tissues between the HART and CF groups, except for early radiation esophagitis.137 patients could be evaluated for immediate response (HART 60,CF 77). The overall response rate(CR+PR)was significantly higher in the HART group (80%) than in the CF group (58 % ),P=0.027.CONCLUSIONS The results indicate that 1)HART can be tolerated by most patients with moderate toxicity. 2)HART improves the immediate response of the tumor in patients with NSCLC.

关 键 词：肺肿瘤 非小细胞肺癌 放射疗法 

分 类 号：R734.2[医药卫生—肿瘤]